For the quarter ending 2026-03-31, VBIO has $38,215K in assets. $19,667K in debts. $7,215K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 7,215 | |||
| Prepaid expenses and other current assets | 687 | |||
| Inventory, net | 750 | |||
| Current assets of discontinued operations | 0 | |||
| Total current assets | 8,652 | |||
| Property and equipment, gross | 12,664 | |||
| Less accumulated depreciation | 20 | |||
| Property and equipment, net | 12,644 | |||
| Deferred offering costs | 555 | |||
| Licensed technology, net | 2,243 | |||
| Right-of-use assets, operating lease | 10,086 | |||
| Goodwill | 3,457 | |||
| Restricted cash | 368 | |||
| Other assets | 210 | |||
| Total assets | 38,215 | |||
| Accounts payable | 629 | |||
| Accrued expenses | 1,490 | |||
| Operating lease liabilities, current | 492 | |||
| Current liabilities of discontinued operations | 4 | |||
| Total current liabilities | 2,615 | |||
| Convertible note payable, net | 6,899 | |||
| Derivative liability | 259 | |||
| Operating lease liabilities, non-current | 9,643 | |||
| Other non-current liabilities | 251 | |||
| Total liabilities | 19,667 | |||
| Temporary equity-Series BPreferred Stock | 1,420 | |||
| Temporary equity-Series CPreferred Stock | 6,066 | |||
| Common stock, 0.0001 par value, 200,000,000 shares authorized 2,879,857 and 2,525,778 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 2 | |||
| Additional paid in capital | 70,094 | |||
| Accumulated deficit | -59,034 | |||
| Total stockholders equity | 11,062 | |||
| Total liabilities, temporary equity and stockholders' equity | 38,215 | |||
Valion Bio, Inc. (VBIO)
Valion Bio, Inc. (VBIO)